Efficacy of aflibercept in patients with neovascular age-related macular degeneration when combined with cataract surgery

QR Code

Efficacy of aflibercept in patients with neovascular age-related macular degeneration when combined with cataract surgery

Purpose: to study the effectiveness of aflibercept in the treatment of neovascular age-related macular degeneration (AMD) combined with cataract phacoemulsification with intraocular lens (IOL) implantation. Material and methods. A short-term, prospective, controlled, non randomized comparative study...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. A. Kuznetsov, E. V. Tur, A. V. Zurochka, V. S. Rykun
Format:	Article
Language:	Russian
Published:	Real Time Ltd 2018-10-01
Series:	Российский офтальмологический журнал
Subjects:	афлиберцепт возрастная макулярная дегенерация анти-vegf терапия мультиплексный анализ aflibercept age-related macular degeneration anti-vegf therapy multiplex analysis
Online Access:	https://roj.igb.ru/jour/article/view/119
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

THE PROGNOSTIC VALUE OF PHARMACOLOGICAL AND GENETIC TESTING IN MEDICAL THERAPY OF AGE-RELATED MACULAR DEGENERATION
by: N. A. Bakunina, et al.
Published: (2018-10-01)

Aflibercept for the therapy of retinal diseases. A review of clinical studies
by: T. D. Okhotsimskaya, et al.
Published: (2018-10-01)

Efficacy and Safety of Aflibercept Biosimilars Relative to Reference Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis
by: Aljuhani HS, et al.
Published: (2025-06-01)

Optimizing the use of angiogenesis inhibitor in neovascular age-related macular degeneration
by: F. A. Bakhritdinova, et al.
Published: (2018-10-01)

The Effectiveness of Retinalamin® Administered by Various Intramuscular Injection Timings in the Treatment of Patients with the Dry Form of Age- Related Macular Degeneration
by: V. V. Neroev, et al.
Published: (2018-10-01)

Pathogenetic issues of retinal dystrophies associated with myopia and agerelated macular degeneration
by: I. B. Alekseev, et al.
Published: (2018-10-01)

Incidence and Clinical Practice of Myopic Macular Neovascularization: A Nationwide Population-Based Cohort Study
by: Masahiro Akada, MD, et al.
Published: (2025-11-01)

The results of a long-term follow up of patients with age-related macular degeneration who received a lutein-containing medication
by: O. V. Zaytseva, et al.
Published: (2018-10-01)

Principles of anti-VEGF dosing in the treatment of neovascular age-related macular degeneration
by: I. E. Ioshin, et al.
Published: (2019-08-01)

THE FIRST EXPERIENCE OF USING ANTI-VEGF THERAPY PRIOR TO CATARACT SURGERY IN PATIENTS WITH DIABETIC MACULAR EDEMA
by: N. A. Malysheva
Published: (2018-10-01)

COMPARISON OF CLINICAL AND REAL-LIFE TRiaLS OF THE EFFECTIVENESS OF ANTI-VEGF THERAPY FOR age-related macular degeneration
by: M. V. Budzinskaya, et al.
Published: (2019-02-01)

Clinical Evaluation of the Effectiveness of Neovascular Age-related Macular Degeneration Combined Treatment
by: L. A. Golota, et al.
Published: (2025-03-01)

Early Real-World Outcomes of Switching to 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration in the United Kingdom
by: Muiz Musadiq, et al.
Published: (2025-06-01)

Analysis of Clinical Study Results Obtained in Patients with Neovascular Age-Related Macular Degeneration in 2005–2020. Review
by: N. A. Gavrilova, et al.
Published: (2022-04-01)

Long-Term Outcomes of Nonadherence to Anti-VEGF Therapy in Advanced Neovascular Age-Related Macular Degeneration
by: A. N. Kulikov, et al.
Published: (2022-10-01)

Clinical effectiveness of nutrof total supplement for Dry age-related macular Degeneration
by: E. N. Eskina, et al.
Published: (2018-10-01)

Pharmacoeconomic research of using aflibercept in patients with the wet age-related macular degeneration
by: S. V. Nedogoda, et al.
Published: (2020-03-01)

Functional express testing and self monitoring in the diagnosis and treatment of macular diseases
by: S. O. Milyutkina, et al.
Published: (2018-10-01)

Structural and Functional Criteria of Neuroprotection Effectiveness after Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration
by: N. S. Zhajvoronok, et al.
Published: (2019-12-01)

The first Russian register of patients with neovascular age-related macular degeneration: a real-world clinical study
by: V. V. Neroev, et al.
Published: (2023-12-01)

Short-term Outcomes of Anti-VEGF therapy in Neovascular Age-related Macular Degeneration with Initially Low Visual Acuity
by: A. N. Kulikov, et al.
Published: (2025-03-01)

Evaluation of Flowmetry Indicators in Patients with a Wet AMD Form during Antiangiogenic Therapy
by: N. Yu. Yousef, et al.
Published: (2019-12-01)

Safety and effectiveness of brolucizumab in patients with neovascular age-related macular degeneration: A phase IV study from India
by: Asim K Ghosh, et al.
Published: (2025-06-01)

Long-term results of anti-VEGF therapy in macular edema caused by central retinal vein occlusion
by: A. B. Galimova, et al.
Published: (2023-12-01)

Experiences of using Aflibercept in diabetic macular edema treatment: data from routine clinical practice
by: E. Yu. Santoro
Published: (2018-12-01)

Optical coherence tomography angiography for choroidal neovascularization in pathological myopia and neovascular age-related macular degeneration in combination with axial myopia in comparative analysis
by: E. A. Drozdova, et al.
Published: (2021-12-01)

Сlinical, functional and morphological results of diabetic macular edema antiangiogenic treatment in patients with diabetes mellitus type two
by: L. K. Moshetova, et al.
Published: (2014-07-01)

THE ROLE OF VASCULAR GROWTH FACTORS IN DIABETIC RETINOPATHY AND MACULAR EDEMA DEVELOPMENT
by: A. G. Iskhakova, et al.
Published: (2018-10-01)

Anti-VEGF therapy of neovascular age-related macular degeneration: from randomized trials to routine clinical practice
by: R. R. Fayzrakhmanov
Published: (2019-06-01)

Pharmacological Analysis of Resistance to Anti-VEGF Therapy
by: M. V. Budzinskaya, et al.
Published: (2019-01-01)

Clinical Phenotypes of Patients with Neovascular Age-Related Macular Degeneration and Poor Response to Aflibercept Treatment
by: V. G. Likhvantseva, et al.
Published: (2022-10-01)

New Qualitative Methods for Assessing the “Fluid” in the Retina in Age-Related Macular Degeneration
by: M. V. Budzinskaya, et al.
Published: (2021-07-01)

Factors determining the compliance of patients receiving anti-VEGF therapy for macular diseases with long-term follow-up in real-life practice
by: E. V. Bobykin, et al.
Published: (2021-03-01)

Efficiency of antiangiogenic therapy for choroidal neovascularization in children
by: L. A. Katargina, et al.
Published: (2024-12-01)

THE EFFICACY AND SAFETY PROFILE OF ADVANCED THERAPY MEDICINAL PRODUCTS IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION
by: R. N. Alyautdin, et al.
Published: (2022-05-01)

An Experimental and Clinical Justification for Prolongation of Action of Anti-VEGF Drug in the “Wet” Form Age-related Macular Degeneration by the Introduction in the Back Subtenon Space on the Basis of Viscous Media
by: R. V. Gaybaryan, et al.
Published: (2017-03-01)

NETWORK APPROACH TO ANALYSIS OF QUANTITATIVE TRAIT LOCI FOR TUMOR NECROSIS FACTOR (TNFα-863, TNFα-308, TNFα-238), VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF-2578, VEGF+936) AND MATRIX METALLOPROTEINASE (ММР2-1306, ММР3-1171, ММР9-1569) GENES IN AGERELATED MACULAR DEGENERATION
by: A. V. Shevchenko, et al.
Published: (2017-10-01)

Risk Factor of Neovascular Agerelated Macular Degeneration Progression after Cataract Surgery
by: V. G. Likhvantseva, et al.
Published: (2024-04-01)

Aqueous−humor biomarkers and real−world efficacy of conbercept for diabetic macular edema: a prospective study in elderly patients
by: Min Xie, et al.
Published: (2025-07-01)

Real-world outcomes of early and deferred anti-VEGF treatment in diabetic macular oedema in patients with type 1 diabetes
by: Joonas Wirkkala, et al.
Published: (2025-12-01)